



Contact: Jenine Anderson
Manager, Corporate Communications
612.777.5629
jenine.anderson@primetherapeutics.com

Prime Therapeutics Signs Risk-Share Agreement for Immunology Drug Cosentyx®

Contract measures persistence to medication, helps control costs for payer clients and members

EAGAN, Minn. – Aug. 16, 2018 – Leading pharmacy benefit manager (PBM) Prime Therapeutics LLC (Prime) has entered into a risk-share agreement with Novartis Pharmaceuticals Corporation (Novartis) for Cosentyx® (secukinumab) as part of Prime’s CareCentered Contracting™ program. Cosentyx is the most prescribed IL-17A treatment for moderate to severe plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis.¹

This agreement is one of the first in the autoimmune category and the collaboration between both companies will help demonstrate the value of a drug relative to its cost for members. The outcomes measured will be members’ persistent use of Cosentyx®.

“At Prime, we look for opportunities that bring measurable value to our clients and members, namely improved health outcomes for members and medicines at the lowest net cost,” said Susan Scheid, vice president for pharmaceutical trade relations at Prime. “With use of biologics and other specialty drugs on the rise, we’re committed to working in collaboration with manufacturers who stand behind the efficacy and safety of their drugs to get the most cost-effective medicines for our members.”

Approximately 50 million Americans have an autoimmune disease (AD).² The National Institutes of Health estimates annual direct care costs for AD to be about \$100 billion.² Autoimmune diseases are the number one drug spend category at Prime, comprising approximately 14 percent of their overall drug spend under the pharmacy benefit.³

About Prime Therapeutics

Prime Therapeutics LLC (Prime) helps people get the medicine they need to feel better and live well. Prime manages pharmacy benefits for health plans, employers, and government programs including Medicare and Medicaid. The company processes claims and offers clinical services for people with complex medical conditions. Prime serves more than 27 million people. It is collectively owned by 18 Blue Cross and Blue Shield Plans, subsidiaries or affiliates of those plans.

For more information, visit www.primetherapeutics.com or follow @Prime_PBM on Twitter.

References

1. Data on File. Cosentyx is Top Prescribed IL-17ATR_x data based on IQVIA National Prescription Audit (NPA) November 2017-January 2018. Novartis Pharmaceuticals Corp; March 2018.
2. Autoimmune Disease Statistics. American Autoimmune Related Diseases Association. <https://www.aarda.org/news-information/statistics/>. Accessed April 4, 2018.
3. Data on File. Prime Spring 2018 Focus on Trend. Prime Therapeutics; Feb 2018.